Guardant Health, Inc. (GH)
Valor JustoFundamental
47
Precio
$176.61
Capitalización Bursátil
$23.94B
Parte 1 · Cuánto vale la empresa
Resumen
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 de septiembre de 2026 with claude-haiku-4-5 — shared with all users
Natera's Signatera is the market-leading blood test for molecular residual disease after cancer surgery, competing directly with Guardant Reveal for the same oncologists and the same post-treatment monitoring reimbursement.
Tempus sells the xF+ liquid biopsy panel and tissue profiling to the same oncology practices, competing with Guardant on both therapy selection and residual disease testing.
A wholly owned Roche subsidiary whose FoundationOne Liquid CDx and FoundationOne CDx panels are the closest rivals to Guardant360 for comprehensive genomic profiling used to pick a cancer therapy.
Acquired by Abbott in March 2026 and no longer separately listed, Exact Sciences sells Cologuard and its own blood-based colorectal screening test to the same primary-care physicians Guardant targets with Shield.
Caris competes for the same oncologists' test orders with whole-exome tissue profiling and its Caris Assure blood platform, covering therapy selection and residual disease alongside Guardant.
GRAIL's Galleri is the leading multi-cancer blood screening test, competing with Guardant's Shield franchise for the same asymptomatic screening population and employer or health-system contracts.
Balance y Liquidez
Ingresos
$1.18B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$-453M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$-233M
Patrimonio Neto Total
$-99M
Pasivo Total
$2.11B
Ratio de Liquidez
4.03
Cobertura de Intereses
97.65
Deuda/EBITDA
-
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$197.04
Precio Actual
$176.61
Margen de Seguridad
+10.4%
Rango de Valor Justo
$187.19 - $206.89
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
-
ROE
419.2%
Ratio P/B
-
P/FCF
-
Margen Bruto
65.0%
ROIC
-23.6%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
-23.6%
WACC
13.1%
ROIC − WACC
-36.7 pp
El ROIC está por debajo del coste del capital: la empresa destruye valor por cada dólar invertido.
Criterios de Análisis Fundamental
Superado (11)
- EPS shows upward trend
- Price CAGR 21.31%
- Gross Margin 65.0%
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 27.9%
- Analyst Consensus 91% Buy
- Share Dilution 2.3%
- Net Margin Trend -38.3% vs -49.9%
- Piotroski F-Score 5/9
Fallido (7)
- ROIC -23.6%
- Operating Margin -39.7%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -246.6%
- Earnings Surprise avg -7.2%
No disponible (9)
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Emitiendo nuevas acciones, diluyendo la participación
Participaciones institucionales
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Dr. Helmy Eltoukhy Ph.D. | Co-Founder, Co-CEO & Chairman | 46 |
| Dr. AmirAli Talasaz Ph.D. | Co-CEO & Director | 45 |
| Mr. Michael Bell | Chief Financial Officer | 56 |
| Dr. Darya Chudova | Chief Technology Officer | 51 |
| Mr. John G. Saia J.D. | Chief Legal Officer & Corporate Secretary | 52 |
| Mr. Andy Ament | Senior Vice President of Operations | - |
| Mr. Kumud Kalia | Chief Information Officer | 59 |
| Zarak Khurshid | Vice President of Investor Relations | - |
| Ms. Gulshan Shaver J.D. | Senior VP of Legal Affairs & Chief Compliance Officer | - |
| Ms. Jennifer Higgins | Senior Vice President of Public Affairs | - |
Riesgo de Auditoría
1
Riesgo del Consejo
7
Riesgo de Compensación
7
Riesgo de Derechos del Accionista
8
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Documentos
- Ver documento
Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2026-02-19
- Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-07-30
- Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-07-30
via SEC EDGAR
Historial de Resultados
via SEC EDGAR
Latest News
Recent headlines for GH, sourced from Markets Gazette.
- 5/20/2026POSITIVEGuardant Health Secures FDA Approval For Expanded Liquid Biopsy Test
Guardant Health has received FDA approval for an expanded use of its Guardant360 Liquid CDx test. This blood-based cancer profiling tool now offers broader diagnostic capabilities, a significant step forward in non-invasive oncology diagnostics. The expanded approval is expected to enhance the test's utility for a wider range of cancer patients and treatment decisions. For investors, this regulatory milestone signifies strong product development and market potential, potentially leading to increased adoption and revenue growth for Guardant Health.
via Markets Gazette